FGD3 and benign neoplasm: Benign tumors (Fig 5A) and breast adenocarcinomas in lower stages (Fig 5B-C) showed strong expression of FGD3, whereas late-stage breast adenocarcinomas in higher stages (Fig 5D-F) showed mild to weak expression.